MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
13 déc. 2023 18h16 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
11 déc. 2023 11h27 HE
|
Beckley Retreats
Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
16 nov. 2023 08h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Beckley Waves Acquires Nue Life
26 oct. 2023 09h00 HE
|
Beckley Waves
Beckley Waves Acquires Nue Life
Addition of Ketamine Assisted Therapy Provider to the Beckley Waves Portfolio Strengthens its Network of Psychedelic Care
PS2023: The Virtual Trip Unveils Latest Video Release Featuring Michael Pollan, Melissa Etheridge, and More
09 oct. 2023 15h13 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
PS2023: The Virtual Trip adds 40+ conference sessions in MAPS’ ongoing effort to provide broad access to Psychedelic Science 2023.
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
26 juil. 2023 07h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
13 juil. 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
10 juil. 2023 07h30 HE
|
Incannex Healthcare
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
23 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Beckley Waves Establishes Ethics Council to Guide Industry Standards and Best Practices During Inaugural Summit of The World’s Leaders in Psychedelics
01 juin 2023 09h00 HE
|
Beckley Waves
The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the Burgeoning Psychedelics Sector Experts Involved in the Council Include Paul...